Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
2010 · New England Journal of Medicine · 15K citations
https://doi.org/10.1056/nejmoa1003466
C
Caroline Robert
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.5K
Papers
157.6K
Citations
154
h-index
566
i10-index
Caroline Robert is an academic researcher from SRM Institute of Science and Technology. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Melanoma and MAPK Pathways & CAR-T cell therapy research. The author has an h-index of 154, co-authored 1260 publications.
ORCID: 0000-0002-9493-0238Papers by this author
worksPembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · New England Journal of Medicine · 5,734 citations
https://doi.org/10.1056/nejmoa1503093
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
2016 · European Journal of Cancer · 2,084 citations
https://doi.org/10.1016/j.ejca.2015.11.016
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
2014 · New England Journal of Medicine · 1,825 citations
https://doi.org/10.1056/nejmoa1406037
A decade of immune-checkpoint inhibitors in cancer therapy
2020 · Nature Communications · 1,506 citations
https://doi.org/10.1038/s41467-020-17670-y
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
2017 · New England Journal of Medicine · 1,459 citations
https://doi.org/10.1056/nejmoa1708539
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat